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Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), which caused
novel corona virus disease-2019 (COVID-19) pandemic, necessitated a global demand for studies
related to genes and enzymes of SARS-CoV2. SARS-CoV2 infection depends on the host cell
Angiotensin-Converting Enzyme-2 (ACE2) and Transmembrane Serine Protease-2 (TMPRSS2),
where the virus uses ACE2 for entry and TMPRSS2 for S protein priming. The TMPRSS2 gene
encodes a Transmembrane Protease Serine-2 protein (TMPS2) that belongs to the serine protease
family. There is no crystal structure available for TMPS2, therefore, a homology model was required
to establish a putative 3D structure for the enzyme. A homology model was constructed using
SWISS-MODEL and evaluations were performed through Ramachandran plots, Verify 3D and Protein
Statistical Analysis (ProSA). Molecular dynamics simulations were employed to investigate the
stability of the constructed model. Docking of TMPS2 inhibitors, camostat, nafamostat, gabexate,
and sivelestat, using Molecular Operating Environment (MOE) software, into the constructed model
was performed and the protein-ligand complexes were subjected to MD simulations and computational
binding affinity calculations. These in silico studies determined the tertiary structure of TMPS2
amino acid sequence and predicted how ligands bind to the model, which is important for drug
development for the prevention and treatment of COVID-19.
Keywords: TMPS2; SARS-CoV2; homology model; molecular dynamics
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1. Introduction
Emerging respiratory diseases such as severe acute respiratory syndrome coronavirus (SARS)
is a vital threat to public health. New emerging diseases remain a cause of outbreaks, epidemics,
and pandemics [1,2]. A new fatal respiratory virus in Wuhan, China, was recently identified in
mid-December 2019. The RNA virus, isolated from the patients’ bronchoalveolar fluid, was investigated
by Metagenomic RNA Sequencing. This RNA virus was identified by the phylogenetic study of
the complete viral genome to be a member of the Coronaviridae family; the SARS-like coronavirus
community (Betacoronavirus genus, Sarbecovirus subgenus) [3–5]. The new emerging respiratory
virus was named Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV2) by the World
Health Organization (WHO) and the disease is now referred to as coronavirus-19 (COVID-19).
Coronaviruses are species of Nidoviral viruses, including Coronaviridae, Arteriviridae,
Roniviridae, and Mesoniviridae [6,7]. The Coronaviridae virus family is divided into two subfamilies:
four genera coronavirinae (Alpha, Beta, Gamma, and Delta Coronavirus), and torovirinae [8].
The genera of the Beta coronavirus include respiratory viruses such as SARS, MERS coV,
and SARS-CoV2.
Coronaviruses encode four structural proteins in their genomes: Spike (S), Glycoprotein (E),
Nucleocapsid (N), and Envelope (E) proteins. The viral attachment protein, which may bind the
virion to a host receptor, is considered to be the (S) protein [8]. Angiotensin Converting Enzyme 2
(ACE2) is part of the renin-angiotensin system and its expression protects against acute respiratory
distress [9,10]. SARS-CoV employs ACE2 as a host cell entry receptor [11,12]. ACE2, with some
mutations in key residues of the SARS-CoV2 (S) protein, was also recognized as the entry receptor
for SARS-CoV2 [13,14]. There are, however, indications that the SARS-CoV2 (S) protein binds to the
receptor with an affinity much higher than that observed for the SARS-CoV (S) protein, which may
play a major role in the rapid spread of COVID-19 worldwide [15]. ACE2 had been considered
as the entry receptor [11,16], while (S) protein priming is performed by the transmembrane serin
proteases type II TMPRSS2 [17–19]. However, the viral spread and pathogenesis of the infected host
was shown to involve TMPRSS2 activities [20–22] (Figure 1). The TMPRSS2 gene codes for the TMPS2
protein, which is present in all possible targets of SARS-CoV-2 infection, including airway epithelial
cells, cardiac endothelium, microvascular endothelial cells, kidney, and digestive tract [23]. Therefore,
targeting TMPS2 might represent a suitable approach for both preventing viral infection and treatment
of severely ill patients [24].
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Figure 1. Therapeutic approaches for treatment of covid-19 either by ACE2 receptor blockers, TMPS2
inhibitors or spike vaccine.
The TMPS2 inhibitors; camostat mesylate and nafamostat mesylate were found to slow down cell
infection by SARS-CoV in preclinical models [25–27]. Nafamostat and camostat have anti-inflammatory
activity in the airways by reducing inflammatory cytokine production in a chronic allergen-induced
asthma model [28,29]. Furthermore, nafamostat can inhibit the coagulation and fibrinolytic systems,
the kallikreinkinin system and activate protease-activated receptors [30].
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Consequently, the anti-inflammatory, anti-coagulant, and fibrinolytic properties of camostat and
nafamostat might contribute to the reduction of symptoms and complications occurring in COVID-19
patients. Both agents are approved in Japan for treatment of pancreatitis [31] and nafamostat is
also used as an anticoagulant in extracorporeal circulation [32]. The introduction of nafamostat in
addition to antivirals such as lopinavir and hydroxychloroquine in the treatment of elderly COVID-19
patients with pneumonia, showed clinical and radiological improvement without significant adverse
effects [33].
Gabexate and sivelestat are serine protease inhibitors marketed in Italy and Japan for the treatment
of pancreatitis and have a mechanism similar to nafamostat and camostat (i.e., inhibition of TMPS2).
To our knowledge, there is no crystal structure for TMPS2 available in the Protein Data Bank
(PDB), which necessitates the construction of a three-dimensional (3D) structure model to determine
the protein architecture and binding interactions of TMPS2 inhibitors to facilitate the improvement of
drug design research against COVID-19.
2. Results and Discussion
2.1. Homology Searching and Template Identification
The ExPASy proteomics server was used to obtain the amino acid sequence of the target protein
TMPS2. Using the UniProtKB database from the ExPASy server, the amino acid sequence of TMPS2
Homo sapiens in FASTA format was obtained (Figure 2). This protein has a UniProt identifier
O15393-1 [34] and is composed of 492 amino acid residues.
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Figure 2. The amino acid sequence of TMPS2 in FASTA format showing the scavenger receptor
cysteine-rich (SRCR) domain highlighted in yellow (amino acid sequence 150–242) and the serine
peptidase domain highlighted in cyan (amino acid sequence 265–489).
Initial screening for suitable templates was carried out by BLAST analyses against the protein data
bank (PDB) using both SWISS-MODEL [35] and NCBI blastp [36] (Table 1). SWISS-MODEL analysis
revealed 5CE1 and 1Z8G as optimal templates, both of which are crystal structures of transmembrane
protease serine 1 with 33.61 and 33.52% identity, respectively. NCBI blastp analysis identified 6KD5_B,
transmembrane protease serine 13 (peptidase domain) as the first hit with 45.19% identity, followed by
a group of human plasma kallikrein crystal structures (e.g., 6O1G_A) with ~42% identity.
Table 1. Initial screening for possible templates using BLAST and SWISS-MODEL analyses against the
PDB resolved structures.
PDB Code Protein Query Cover E-Value Percent Identity
5CE1_A TMPS1 94% 7e–67 33.61
1Z8G_A TMPS1 69% 4e–62 33.52
6KD5_B TMPS13 47% 3 64 4 .19
6O1G_A Plasma kallikrein 51% 2 61 42.21
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2.2. Homology Modelling
Homology models for TMPS2 were generated using SWISS-MODEL from the four identified
templates, which were subsequently evaluated using MolProbability [37], ProSA [38] and Verify3D [39]
to assess the quality of the models, the data of which is provided in Table 2.
Table 2. Validation data for the four TMPS2 homology models.
Model Ramachandran Outliers ProSA Z-Score Verify3D
Model 1 (5CE1_A template) 3 (Ser208, Ala216, Arg255) −8.67 95.38%
Model 2 (1Z8G_A template) 3 (Ser215, Leu248, Val415) −8.76 91.59%
Model 3 (6KD5_B template) 2 (Pro301, Asn433) −6.80 97.02%
Model 4 (6O1G_A template) 5 (Asn303, Asn304, Phe321, Pro305, Pro369) −6.57 91.56%
Overlap of the four models (Figure 3) showed a high degree of homology between all four models
in the serine peptidase domain, however the greatest coverage was with the models generated from
TMPS1 crystal structures 5CE1 and 1Z8G, which have both the scavenger receptor cysteine rich (SRCR)
and serine peptidase domains.
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Figure . Overlap of the four TMPS2 models gen rated from crystal st uctures 5CE1_A (b ue),
Please ensure that intended meaning has been retained. 1Z8G_A (yellow), 6KD5_B (red) and
6O1G_A (green).
T PS2 odels 1 (5CE1_ ) and 2 (1Z8 _ ) ere co parable using Ra ac a ra l t,
Verify3D and ProSA (Tables S1 and S2 and Figures 1–S6 i S le e tar Materials). evaluate
further, both models were subjected to 150 ns molecular dynamics (MD) simulations using the Desmond
programme of Maestro [40]. Model 1 started from the Root Mean Square Deviation (RMS ) 1.40 Å
and rapidly reached an equilibrium plateau with a final RMSD of 2.86 Å at 150 ns. Model 2 started
with a higher RMSD of 2.10 Å but showed more fluctuation and only began to plateau at around 90 ns
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(RMSD 4.63 Å) with a final RMSD of 4.81 Å at 150 ns (Figure 4). Overlap of the proteins after MD
simulation diverged in the SRCR domain but showed better alignment in the serine peptidase domain
(Figure S7 in Supplementary Materials). From MD simulations, model 1 would appear to be the more
stable system and so was chosen for further studies.
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2.3. T PS2 Structure Evaluation
A blastp analysis was performed using the NCBI server, query transmembrane protease serine
against human sequences in the swissprot database [41]. Details for T PS2 (O1593) and the closest
five matches were obtained from the Uniprot server and are presented in Table 3.
Table 3. Active site and domains of the most homologous TMPS proteins.
Domains
Protein Uniprot ID Active SiteHis/Asp/Ser Cleavage Site
LDL-Receptor
Class A SRCR
Serine
Peptidase X-ray Structure
TMPS1 P05981 203/257 353 162–163 - 54–151 163–405 5CE1, 1Z8G, 1P57
TMPS2 O15393 296/345/441 255–256 112–149 150–242 256–489 -
TMPS3 P57727 257/304/401 2 –217 72–108 109–205 217–449 -
TMPS4 Q9NRS4 245/290/387 204–205 61–93 94–204 205–434 -
TMPS5 Q9H353 258/308/405 217–218 - 112–207 218–453 -
TMPS13 Q9BYE2 366/414/511 325–326 204–226 195–325 326–559 6KD5
SRCR = scavenger receptor cysteine rich; LDL = low-density lipoprotein.
A Clustal Omega [42] alignment was performed on the TMPS proteins. The three amino acids
(His, Asp, Ser) that form the catalytic triad required for peptide bond hydrolysis, the cleavage site
(Arg-Ile/Val-Val-Gly-Gly/Ile) responsible for proteolytic activation, and the disulphide forming cysteine
residues are highly conserved (Figure S8 in Supplementary Materials). TMPS2 most closely aligns
with TMPS3 (41.95%) as illustrated from the percent identity matrix and the cladogram (Figure 5).
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non-catalytic domain [43], formed by Cys172–Cys231 and Cys185–Cys241, and in the serine peptidase
domain by Cys281–Cys297, Cys410–Cys426 and Cys437–Cys465. The catalytic triad of His296,
Asp345 and Ser441 spans the active site with Ser441 on one side and Asp345 and His296 on the other
side of the S1 pocket (Figures 6 and 7). Asp435 sits at the base of the S1 pocket and Ser436 and Asp440
form the right wall. Asp435, Gly462 and Gly472 create a negatively charged S1 site and the combination
of Ser441, Gly462 and Gly472 form a deep hydrophobic pocket to accommodate hydrophobic amino
acids of a peptide substrate. The characteristic oxyanion hole of chymotrypsin family serine protease
enzymes is formed by the backbone of Gly439 and Ser441. The polypeptide binding site is formed by
residues 460–462 (Ser460, Trp461 and Gly462), which would be expected to form an antiparallel β-sheet
with the backbone of the P1-P3 residues of a peptide substrate (Figure 7, Table S3 and Figure S9 in
Supplementary Materials).
l l  , , x FOR PEER REVIEW    
 
 
Figure 5. Percent identity matrix and phylogenic cladogram generated from the Clustal alignment of 
TMPS proteins. 
The protein structure is stabilised by five disulphide bonds, which are found in the SRCR 
non-catalytic domain [43], formed by Cys172–Cys231 and Cys185–Cys241, and in the serine 
peptidase domain by Cys281–Cys297, Cys410–Cys426 and Cys437–Cys465. The catalytic triad of 
His296, Asp345 and Ser441 spans the active site with Ser441 on one side and Asp345 and His296 on 
the other side of the S1 pocket (Figures 6 and 7). Asp435 sits at the base of the S1 pocket and Ser436 
and Asp440 form the right wall. Asp435, Gly462 and Gly472 create a negatively charged S1 site and 
the combination of Ser441, Gly462 and Gly472 form a deep hydrophobic pocket to accommodate 
hydrophobic amino acids of a peptide substrate. The characteristic oxyanion hole of chymotrypsin 
family serine protease enzymes is formed by the backbone of Gly439 and Ser441. The polypeptide 
binding site is formed by residues 460–462 (Ser460, Trp461 and Gly462), which would be expected to 
form an antiparallel β-sheet with the backbone of the P1-P3 residues of a peptide substrate (Figure 7, 
Table S3 and Figure S9 in supplementary materials). 
 
Figure 6. Amino acid sequence of TMPS2 showing α-helices coloured in pink, β-sheets coloured in 
yellow, loops coloured in grey, the catalytic triad residues are surrounded in cyan and the cleavage 
site is surrounded in green. 
i . i i f i - li l i i , - t l i
, loops coloured in grey, the cat lytic triad residues are surrounded in cyan d the cl avage sit
is surro nded in green.
Molecules 2020, 25, 5007 7 of 16
Molecules 2020, 25, x FOR PEER REVIEW 7 of 16 
 
  
(A) (B) 
Figure 7. (A) 3D image of TMPS2 with the position of the catalytic triad (green) in the serine 
peptidase domain shown. The two six-stranded β-barrels (yellow) are positioned either side of the 
catalytic triad. (B) Serine peptidase active site showing the catalytic triad (green), the amino acids 
that form the S1 pocket (light pink) and the two disulfides Cys281-Cys297 and Cys437-Cys465 
(magenta). 
Having established the binding site and amino acids within the S1 pocket, docking was 
performed with ligands to generate TMPS2-ligand complexes. 
2.4. Refinement of TMPS2 Homology Model after MDS and Docking Studies 
The complexes were prepared by docking a database of ligands in the TMPS2-5CE1 homology 
model using MOE [44]. Using site finder, the active site chosen contained Ser441 and the majority of 
the S1 pocket amino acids: Glu389, Tyr416, Asp435, Ser436, Cys437, Gln438, Ser441, Thr459, Ser460, 
Trp461, Gly462, Ser463, Gly464, Cys465, Ala466, Arg470, Pro471, Gly472 and Val473. 
The ligand-protein complexes were subjected to 200 ns molecular dynamics (MD) simulations 
using the Desmond programme of Maestro (Figure 8). 
A B 
  
C D 
  
Figure 7. (A) 3D image of TMPS2 with the position of the catalytic triad (green) in the serine peptidase
domain shown. The two six-stranded β-barrels (y llow) re positioned either side of the catalytic triad.
(B) Serine pepti ase active sit showing the catalytic triad (gr en), the amino acids that for the S1
pocke (light pink) and the two disulfides Cys281-Cys297 and Cy 437-Cys465 (magenta).
Having established the binding site and amino acids within the S1 pocket, docking was performed
with ligands to generate TMPS2-ligand complexes.
2.4. Refinement of TMPS2 Homology Model after MDS and Docking Studies
The complexes were prepared by docking a database of ligands in the TMPS2-5CE1 homology
model using MOE [44]. Using site finder, the active site chosen contained Ser441 and the majority of
the S1 pocket amino acids: Glu389, Tyr416, Asp435, Ser436, Cys437, Gln438, Ser441, Thr459, Ser460,
Trp461, Gly462, Ser463, Gly464, Cys465, Ala466, Arg470, Pro471, Gly472 and Val473.
The ligand-protein complexes were subjected to 200 ns molecular dynamics (MD) simulations
using the Desmond program e of Maestro (Figure 8).
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For camostat, nafamostat and gabexate, the protein equilibrates. However, for sivelestat, the RMSD
is still increasing indicating the protein is undergoing a significant conformational change at the end
of the simulation. Likewise, the ligand RMSD for sivelestat is significantly larger than the RMSD of
the protein indicating that the ligand has diffused away from the initial binding site. The most stable
system is the nafamostat-TMPS2 complex, which equilibrates rapidly, while there are more fluctuations
with camostat and gabexate (Table 4).
Table 4. Protein-ligand RMSD (Å) at 0 and 200 ns.
RMSD (Å) 0 ns RMSD (Å) 200 ns
Ligand-Complex Protein Ligand Protein Ligand
Camostat 2.18 5.32 3.90 5.05
Nafamostat 1.83 4.85 3.21 5.83
Gabexate 2.20 2.98 4.35 5.87
Sivelestat 2.25 2.21 5.07 29.42
Nafamostat was optimal with respect to binding, with the phenyl guanidine group situated
within the S1 pocket through a salt bridge with Asp435 and H-bonding interactions with Asp435,
Ser436, Ser463 and Gly462 (Figure 9). The phenyl ring sits in the hydrophobic pocket composed
of Thr459, Ser460, Trp461 and Val473. The carbonyl oxygen of the ester linkage forms a water
mediated H-bonding interactions with Ser441 and the amidine group forms direct and water mediated
H-bonding interactions with Glu299 (Figure 9). Visualization using MOE also identified an aryl-H
binding interaction between the phenyl ring of nafamostat and the backbone of Cys437 (Figure 9B).
As previously reported [45], the catalytic steps for the cleavage of peptide-like bonds involve an
acyl-enzyme intermediate formation between the substrate and Ser441 followed by the hydrolysis
of the acyl-enzyme intermediate, releasing the cleaved substrate and restoring the active form of
the enzyme. Nafamostat with its guanidinobenzoate moiety can inhibit TMPS2 by mimicking the
natural substrates, where the ester group, resembling a peptide bond, can react with the catalytic
serine forming the acyl-enzyme intermediate while the guanidinobenzoyl group becomes linked to the
catalytic serine Ser441, rendering nafamostat an effective chemical inhibitor, which meets our findings
after MDS.
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Camostat and gabexate were similar to nafamostat in the binding profiles of the guanidine group
with the salt bridge formed with Asp435 and H-bonding interactions, direct or water mediated with
Asp435, Ser436, Ser463 and Gly464 for camostat (Figure 10), and with Asp435, Gly464 and Arg470 for
gabexate (Figure 11). Camostat formed H-bonding interaction between the ester and amide carbonyl
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oxygen atoms on the opposite side with water solvation molecules, while gabexate formed H-bonding
interaction between the two ester carbonyl oxygens and water of solvation and the terminal ester also
formed a H-bonding interaction with His296 (Figures 10 and 11).
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For the ligand-TMPS2 complexes of camostat, nafamostate and gabexate complexes, the mean
∆G (bind) was calculated [46] over two time frames, from 100–200 ns and the final 10 ns (190–200 ns)
of the MD simulation (Table 5). The ∆G values indicate positioning within the TMPS2 protein was
optimal for nafamostat, with ∆G values of −60.99 ± 4.27 and −61.47 ± 4.44 kcal/mol, respectively over
the two timeframes. Thus, nafamostat would appear to have better binding affinity, which supports
the observations from protein-ligand RMSD (Figure 8B) and interaction figures (Figure 9).
Table 5. Computational binding affinity (∆G) of the ligand-protein complexes.
Complex ∆G (kcal/mol) 100–200 ns ∆G (kcal/mol) 190–200 ns
Camostat-TMPS2 −48.87 ± 5.07 −46.24 ± 4.42
Nafamostat-TMPS2 −60.99 ± 4.27 −61.47 ± 4.44
Gabexate-TMPS2 −54.37 ± 4.86 −51.91 ± 4.86
Protein interactions with the ligand could be categorized by type and summarized, as shown
in the plots below (Figure 13), where the protein-ligand interactions (or ‘contacts’) are categorized
into four types: hydrogen bonds, hydrophobic, ionic and water bridges. This can also be visualised
from the ligand-protein contacts 2D summary over the course of the 200 ns simulation (Figure S10 in
Supplementary Materials).
Limitations of this study:
Although MD is a robust computational method for the study of protein-ligand complexes,
the results described here are theoretical, therefore experimental enzyme inhibition (IC50) assays,
with the appropriate replicas, against TMPS2 are required to validate the theoretical findings.
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3. Materials and Methods
3.1. Transmembrane Protease Serine 2 (TMPS2_HUMAN) Molecular Modelling
The homologous sequences for building the 3D structure were searched using NCBI-BlastP (basic
local alignment search tool). For alignments, BLOSUM62 substitution matrix was used as a comparison
matrix. Clustal Omega from the European Bioinformatics Institute (EBI) was used to determine the
conserved areas between the selected proteins and target protein TMPS2. SWISS-MODEL server
accessible via ExPASy web server was used in comparative modelling of TMPS2. The constructed
models were then evaluated.
3.2. Refinement and Evaluation of the Model
The Ramachandran plot was provided by the MolProbity server at Duke Biochemistry, US [37].
The PDB files of the homology models were uploaded. H-atoms were added, and the gaps were
filled in the protein backbone with JiffiLoop (beta-test). The results were displayed and subdivided
into regions of favoured, allowed, and disallowed [47]. The output data demonstrated a comparison
between atom contacts, protein geometry, and peptide omegas in tables. A file of the best model in a
PDB format was uploaded on ProSA (Protein Structure Analysis) [38] and the Z-score was calculated.
Three parameters for each amino acid; secondary structure, degree of buried surface area, and fraction
of side chain area that was covered by polar atoms were evaluated by Verify 3D service [39]. For each
residue in the structure, these three parameters were evaluated, and a correlation was determined
between the observed parameters and the ideal ones to which they were assigned.
3.3. Molecular Dynamic Simulation (MDS) and Docking Studies
Molecular docking and molecular dynamics simulations were performed as previously
described [48]. Briefly docking studies using the TMPS2 homology model to generate PDB files of the
TMPS2-ligand complexes were performed using MOE [44] until an RMSD gradient of 0.01 Kcal/mol/Å
with the MMFF94 forcefield (ligands) and partial charges were automatically calculated. Docking was
performed using the Alpha Triangle placement to determine the poses, refinement of the results was
done using the MMFF94 forcefield, and rescoring of the refined results using the London ∆G scoring
function was applied. The output database dock file was created with different poses for each ligand
and arranged according to the final score function (S), which is the score of the last stage that was not
set to zero.
Molecular dynamics simulations were run on the TMPS2-ligand complexes with the PDB files first
optimised with protein preparation wizard in Maestro by assigning bond orders, adding hydrogen,
and correcting incorrect bond types. A default quick relaxation protocol was used to minimise the
MD systems with the Desmond programme. The orthorhombic water box allowed for a 10 Å buffer
region between protein atoms and box sides. Overlapping water molecules were deleted, and the
systems were neutralised with Na+ ions and salt concentration 0.15 M. Force-field parameters for the
complexes were assigned using the OPLS_ 2005 forcefield, that is, a 200 ns molecular dynamic run in
the NPT ensemble (T = 300 K) at a constant pressure of 1 bar. Energy and trajectory atomic coordinate
data were recorded at each 1.2 ns. Prime/MMGBAS, available in Schrödinger Prime suite, was used to
calculate the binding free energy of the ligands with TMPS2.
∆G (bind) = E_complex (minimised) − (E_ligand (minimised) + E_receptor (minimised))
Two mean ∆G (bind) values were calculated from (1) each 5 frames of the final 100 ns, and (2)
each frame of the final 10 ns of the MD simulation. The average generated ∆G was from each energy
minimised frame using the equation shown above.
4. Conclusions
In this study, a high-quality homology model of the 3D human TMPS2 was constructed to enable
investigation of TMPS2 as a promising drug target for the development of therapeutics in the treatment
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of SARS-CoV2. Molecular dynamics simulations were performed, and the active site conserved amino
acids were selected as a docking site for camostat, nafamostat, gabexate, and sivelestat. Quite clearly
nafamostat has optimal binding owing to its ability to anchor both ends of its structure through a salt
bridge with Asp345 and the guanidine group, and H-bonding with Glu299 and the amidine group.
Camostat and gabexate are able to anchor the guanidine group effectively via salt bridge formation
with Asp345, however the dimethylamide of camostat is not able to form an anchor with the protein,
while gabexate, which is a more flexible molecule, was able to form a H-bonding interaction with
His296. Computational binding affinity (∆G) studies support the findings of the MD studies and the
requirement of the basic guanidine moiety, or equivalent functional group, in the salt bridge formation
with Asp345. Sivelestat, which lacks a basic functional group, is unable to form a tether with Asp435
and rather diffuses from the S1 site to a position where the acidic carboxylate group of sivelestat can
form a salt bridge with a basic amino acid, Arg316 (Figure S11 in Supplementary Materials).
The studies also indicate the preference for a basic moiety at the other end of the inhibitor to
form an ionic bond with an acidic amino acid and secure the inhibitor within the S1 binding pocket as
observed with nafamostat with an amidine group. The ability of gabexate to tether the other end of
its structure through a H-bonding interaction provides some scope to investigate additional H-bond
forming functional groups. In addition, the optimal length and flexibility of a TMPS2 inhibitor ligand
to fit and bind within the S1 pocket would warrant further investigation through inhibitor design.
Supplementary Materials: Table S1: Stereochemical quality assessment of TMPS2 model 1 (5CE1_A template),
Table S2: Stereochemical quality assessment of TMPS2 model 2 (1Z8G_A template), Table S3: Comparison
between TMPS2 and the template 5CE1_A, Figure S1: Ramachandran plot for TMPS2 model 1 (5CE1_A template);
92.2% (317/344) of all residues were in favoured (98%) regions, 99.1% (341/344) of all residues were in allowed
(>99.8%) regions. There were 3 outliers (phi, psi): 208 Ser (−58.3, −174.6), 216 Ala (−25.8, −45.7) and 255 Arg
(88.3, 25.7), Figure S2: Ramachandran plot for TMPS2 model 2 (1Z8G_A template); 94.2% (323/343) of all residues
were in favoured (98%) regions, 99.1% (340/343) of all residues were in allowed (>99.8%) regions. There were
3 outliers (phi, psi): 215 Ser (−56.0, 2.4), 248 Leu (−50.9, −74.7) and 415 Val (−104.8, −94.8), Figure S3: Z-scores of
TMPS2 model 1 (5CE1_A template) determined by X-ray crystallography (light blue) or NMR spectroscopy (dark
blue), and local model quality by plotting energies as a function of amino acid sequence position, a positive value
indicates erroneous parts; most of the amino acids gave negative values, Figure S4: Z-scores of TMPS2 model 2
(1Z8G_A template) determined by X-ray crystallography (light blue) or NMR spectroscopy (dark blue), and local
model quality by plotting energies as a function of amino acid sequence position, a positive value indicates
erroneous parts; most of the amino acids gave negative values, Figure S5: Verify 3D results for model 1 (5CE1_A
template) showing that the model passes in the 3D/1D profile, Figure S6: Verify 3D results for model 2 (1Z8G_A
template) showing that the model passes in the 3D/1D profile, Figure S7: Overlap of 5CE1_A (blue) and 1Z8G_A
(yellow) after MD simulation, Figure S8: Sequence alignment of TMPS enzymes using Clustal O in which "∗"
means that the residues are identical, ":" means that conserved substitutions have been observed, "." means that
semi-conserved substitutions are observed. The SRCR domain is indicated in blue lettering, cysteine residues
involved in disulphide bond formation are highlighted in yellow, the catalytic triad residues are highlighted in
cyan and the cleavage site is highlighted in pink, Figure S9: Comparison between the secondary structure of
TMPS2 and the template 5CE1_A after alignment and superimposition using MOE software, showing α-helices
as red lines, β-sheets as yellow arrows and loops as blue lines, Figure S10: A schematic of detailed ligand atom
interactions of (A) camostat, (B) nafamostat, (c) gabexate and (D) sivelestat with the protein residues of TMPS2
protein. Interactions that occur more than 30.0% of the simulation time in the selected trajectory (0 through 200 ns)
are shown, Figure S11: 2D Ligand interactions of sivelestat in TMPS2 protein.
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